[Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy]. / Le médicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogestérone) comme traitement hormonal de substitution a la ménopause.
Rev Med Liege
; 66(4): 209-14, 2011 Apr.
Article
en Fr
| MEDLINE
| ID: mdl-21638840
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Terapia de Reemplazo de Estrógeno
/
Didrogesterona
/
Estradiol
Tipo de estudio:
Guideline
Límite:
Female
/
Humans
Idioma:
Fr
Revista:
Rev Med Liege
Año:
2011
Tipo del documento:
Article
País de afiliación:
Bélgica
Pais de publicación:
Bélgica